The spectrum of prostate cancer care: from curative intent to palliation.
Prostate cancer is one of the most prevalent malignancies affecting men in the developed world. A spectrum of disease states exists and management is tailored to individual patients. Increasing public awareness and prostate-specific antigen testing have led to earlier detection and the possibility of cure but have increased the risk of overtreatment of indolent disease. Advances in curative modalities have reduced side effects and offer patients a choice of treatments. Nonetheless, many need no intervention and may be safely treated with active monitoring. Choice and timing of therapy for locally advanced and recurrent disease are variable, with potential benefits of early intervention counterbalanced by side effects of treatment. Progress has been made in the management of advanced disease; skeletal-related events have been reduced and survival has been increased. This review examines the evidence and rationale behind the treatment options from curative intent to management of locally advanced disease and palliation of metastatic disease.
Ali
Ased S M
AS
Section of Oncology, University of Sheffield, Academic Urology Unit, Royal Hallamshire Hospital, Sheffield, UK.
Hamdy
Freddie C
FC
D000726:Androgen Antagonists / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010166:Palliative Care; D011159:Population Surveillance; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016879:Salvage Therapy; D017211:Treatment Failure
D000726:Androgen Antagonists; D052246:Cyclooxygenase 2 Inhibitors; D004164:Diphosphonates